Novo Nordisk's John Kuckelman Talks Eli Lilly Obesity Drug Ads
About this episode
John Kuckelman discusses Novo Nordisk's accusations against Eli Lilly regarding misleading advertising for obesity drugs.
Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint. See omnystudio.com/listener for privacy information.
More episodes of Bloomberg Talks
- Charles Schwab CEO Rick Wurster Talks Earnings, AI, Prediction Markets
- Bermuda Premier David Burt Talks On-Chain Economy Initiative
- GE CEO Larry Culp Talks 2026 Outlook
- Hasbro CEO Chris Cocks Talks 2026 Outlook, Earnings
- Imax CEO Rich Gelfond Talks "The Odyssey' Sellouts
- UNGA President Baerbock Talks "Critical Moment" For Organization's Future
Explore listener stats, chart rankings, contacts and more on the Bloomberg Talks podcast page.